Elevance Health, Inc. $ELV Stock: Quadrant Capital Group LLC Lowers Holdings

Quadrant Capital Group LLC trimmed its position in shares of Elevance Health, Inc. (NYSE:ELV) by 34.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,846 shares of the company’s stock after selling 1,529 shares during the quarter. Quadrant Capital Group LLC’s holdings in Elevance Health were worth $1,210,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Pinnacle Associates Ltd. lifted its holdings in Elevance Health by 7.4% in the third quarter. Pinnacle Associates Ltd. now owns 2,922 shares of the company’s stock valued at $1,136,000 after buying an additional 201 shares during the period. Robeco Institutional Asset Management B.V. lifted its holdings in shares of Elevance Health by 94.0% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 332,778 shares of the company’s stock worth $129,391,000 after purchasing an additional 161,278 shares in the last quarter. Revisor Wealth Management LLC grew its holdings in shares of Elevance Health by 6.6% during the third quarter. Revisor Wealth Management LLC now owns 4,404 shares of the company’s stock valued at $1,801,000 after buying an additional 274 shares during the last quarter. Bank Pictet & Cie Europe AG boosted its stake in Elevance Health by 5.8% during the 3rd quarter. Bank Pictet & Cie Europe AG now owns 1,654 shares of the company’s stock valued at $643,000 after purchasing an additional 90 shares during the last quarter. Finally, 55 North Private Wealth LLC raised its position in Elevance Health by 4.5% in the 3rd quarter. 55 North Private Wealth LLC now owns 598 shares of the company’s stock valued at $233,000 after buying an additional 26 shares during the last quarter. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Elevance Health News Roundup

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Third-quarter adjusted earnings per share rose 15.9% and exceeded consensus, while revenue also topped expectations. Elevance raised its 2026 adjusted EPS outlook to at least $29, citing disciplined cost management and improved medical-cost trends. Elevance Health Q3 Results
• Positive Sentiment: Carelon’s expansion and clinical programs remain growth drivers; its cancer program reportedly reduced avoidable inpatient admissions by 15%. Management also highlighted actions intended to improve Medicaid profitability. ELV Q3 Deep Dive
• Positive Sentiment: TD Cowen raised its price target to $495 from $465 and maintained a Buy rating, indicating continued confidence in the earnings recovery. TD Cowen Rating
• Positive Sentiment: Elevance declared a quarterly dividend of $1.72 per share, supporting its shareholder-return profile. Elevance Health Dividend
• Neutral Sentiment: Elevance appointed Jeff Park as president of Carelon in a services leadership shift. The move may support execution, but its financial impact is not yet clear. Carelon Leadership Shift
• Neutral Sentiment: Morgan Stanley lifted its target to $449 from $404 but retained an Equal Weight rating, suggesting limited upside after the recent advance. Morgan Stanley Rating
• Negative Sentiment: Officer Mark B. Kaye disclosed an intent to sell 10,584 shares valued at approximately $4.66 million. While the sale may be routine, it can weigh on sentiment near a 52-week high. Officer Share Sale
• Negative Sentiment: Analysts continue to flag sustainability risks: nine-month operating gain declined, and Medicaid margins remain under pressure. Robert W. Baird kept a Neutral rating with a $406 target, below the current trading level. Elevance Health Earnings Analysis

Analyst Upgrades and Downgrades

ELV has been the topic of several recent analyst reports. UBS Group lifted their target price on shares of Elevance Health from $460.00 to $523.00 and gave the stock a “buy” rating in a research report on Thursday. The Goldman Sachs Group restated a “neutral” rating and issued a $451.00 price objective on shares of Elevance Health in a research note on Friday. Wall Street Zen lowered Elevance Health from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Robert W. Baird boosted their price target on shares of Elevance Health from $393.00 to $406.00 and gave the stock a “neutral” rating in a report on Thursday. Finally, Barclays increased their price target on shares of Elevance Health from $469.00 to $472.00 and gave the company an “overweight” rating in a research report on Thursday. Fifteen analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $455.57.

Elevance Health Stock Performance

Shares of ELV opened at $440.05 on Friday. The stock’s fifty day moving average price is $408.32 and its two-hundred day moving average price is $390.89. Elevance Health, Inc. has a 1 year low of $274.84 and a 1 year high of $450.69. The firm has a market cap of $95.43 billion, a PE ratio of 18.77, a PEG ratio of 2.32 and a beta of 0.70. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.47 and a quick ratio of 1.52.

Elevance Health (NYSE:ELV) last released its quarterly earnings data on Wednesday, October 21st. The company reported $6.99 EPS for the quarter, beating the consensus estimate of $4.71 by $2.28. The business had revenue of $50.44 billion for the quarter, compared to the consensus estimate of $49.28 billion. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The company’s revenue was up .7% compared to the same quarter last year. During the same period in the prior year, the firm earned $6.03 earnings per share. On average, equities research analysts forecast that Elevance Health, Inc. will post 27.09 EPS for the current year.

Elevance Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Friday, December 4th will be paid a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a yield of 1.6%. The ex-dividend date is Friday, December 4th. Elevance Health’s payout ratio is currently 29.34%.

Insider Transactions at Elevance Health

In other Elevance Health news, CFO Mark Kaye sold 10,584 shares of the business’s stock in a transaction on Thursday, October 22nd. The shares were sold at an average price of $440.13, for a total transaction of $4,658,335.92. Following the sale, the chief financial officer owned 19,919 shares of the company’s stock, valued at $8,766,949.47. The trade was a 34.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.34% of the stock is owned by insiders.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.